Why Shares of Sarepta Therapeutics Inc Are Falling Today
A capital raise disappoints investors, sending shares lower.
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Which of these two companies will win the race to successfully develop the first Duchenne muscular dystrophy treatment? Our team of contributors weigh in.
Sarepta's Less-Than-Perfect Data
Give the drugmaker a pass on its historical control data.
Why Sarepta Therapeutics Shares Are Soaring Today
Sarepta has released positive efficacy and safety data relating to eteplirsen, its therapy for Duchenne muscular dystrophy.